{ "name": "Synptide GLP-1 Clinical Trials", "version": "1.0", "updated": "2026-07-12", "source": "ClinicalTrials.gov API v2", "sourceLicense": "Public domain (U.S. Government work)", "license": "CC BY 4.0 for the Synptide compound tagging; underlying trial records are public domain", "citation": "Synptide GLP-1 Clinical Trials (synptide.com/datasets), sourced from ClinicalTrials.gov", "count": 284, "trials": [ { "nctId": "NCT07027969", "title": "Metabolic Surgery for Atrial Fibrillation Elimination", "status": "Not yet recruiting", "phase": "PHASE4", "sponsor": "Ali Aminian", "conditions": "Atrial Fibrillation; Obesity and Obesity-related Medical Conditions", "interventions": "Roux-en-Y Gastric Bypass or Sleeve Gastrectomy; Anti-Obesity Medication (AOM) treatment", "enrollment": "100", "startDate": "2026-11-01", "completionDate": "2029-12-31", "hasResults": "no", "compounds": "liraglutide; dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07027969" }, { "nctId": "NCT07677891", "title": "Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus", "status": "Not yet recruiting", "phase": "PHASE2", "sponsor": "ProGen. Co., Ltd.", "conditions": "Type 2 Diabetes", "interventions": "PG-102(MG12); Dulaglutide", "enrollment": "60", "startDate": "2026-10", "completionDate": "2027-05", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07677891" }, { "nctId": "NCT07668336", "title": "A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes", "status": "Not yet recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Diabetes Mellitus, Type 2", "interventions": "Orforglipron; Dulaglutide", "enrollment": "170", "startDate": "2026-09", "completionDate": "2030-03", "hasResults": "no", "compounds": "dulaglutide; orforglipron", "url": "https://clinicaltrials.gov/study/NCT07668336" }, { "nctId": "NCT07357740", "title": "A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes", "status": "Withdrawn", "phase": "PHASE2", "sponsor": "Novo Nordisk A/S", "conditions": "Diabetes Mellitus, Type 2", "interventions": "CagriSema; Placebo CagriSema", "enrollment": "0", "startDate": "2026-08-27", "completionDate": "2027-08-25", "hasResults": "no", "compounds": "semaglutide; cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07357740" }, { "nctId": "NCT07282613", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes", "status": "Not yet recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Diabetes Mellitus, Type 2", "interventions": "CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)", "enrollment": "80", "startDate": "2026-08-04", "completionDate": "2029-09-07", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07282613" }, { "nctId": "NCT07693608", "title": "An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder", "status": "Not yet recruiting", "phase": "PHASE2", "sponsor": "University of Texas Southwestern Medical Center", "conditions": "Obesity; Methamphetamine Use Disorder; Cocaine Use Disorder; Stimulant Use Disorders", "interventions": "Tirzepatide", "enrollment": "45", "startDate": "2026-08-01", "completionDate": "2030-02-01", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07693608" }, { "nctId": "NCT07676331", "title": "Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial", "status": "Not yet recruiting", "phase": "PHASE2", "sponsor": "Universitaire Ziekenhuizen KU Leuven", "conditions": "Hormone-receptor-positive Breast Cancer; Early Breast Cancer", "interventions": "Tirzepatide; Letrozole (Aromatase Inhibitors)", "enrollment": "168", "startDate": "2026-08-01", "completionDate": "2028-03-01", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07676331" }, { "nctId": "NCT07671248", "title": "Tirzepatide in the Treatment of Cannabis Use Disorder", "status": "Not yet recruiting", "phase": "PHASE3", "sponsor": "McMaster University", "conditions": "Cannabis Use Disorder, Moderate; Cannabis Use Disorder, Severe", "interventions": "Tirzepatide", "enrollment": "15", "startDate": "2026-08-01", "completionDate": "2028-07-31", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07671248" }, { "nctId": "NCT07671391", "title": "A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants", "status": "Not yet recruiting", "phase": "PHASE2", "sponsor": "Shanghai Zhongshan Hospital", "conditions": "Obesity Adult Onset", "interventions": "LAE102 +Tirzepatide; LAE102 placebo,+Tirzepatide", "enrollment": "60", "startDate": "2026-08", "completionDate": "2027-07", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07671391" }, { "nctId": "NCT07668765", "title": "GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity", "status": "Not yet recruiting", "phase": "N/A", "sponsor": "Gazi University", "conditions": "Morbid Obesity; Anorectal Diseases; Drug-Related Side Effects and Adverse Reactions; Constipation; Diarrhea", "interventions": "GLP-1 receptor agonist therapy", "enrollment": "100", "startDate": "2026-08", "completionDate": "2027-04", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07668765" }, { "nctId": "NCT07695454", "title": "Imaging in Semaglutide Study", "status": "Not yet recruiting", "phase": "N/A", "sponsor": "The Cleveland Clinic", "conditions": "Type 2 Diabetes; BMI Greater Than 30", "interventions": "31P-MRS and MRI", "enrollment": "10", "startDate": "2026-07-15", "completionDate": "2026-12-30", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07695454" }, { "nctId": "NCT07627191", "title": "GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer", "status": "Not yet recruiting", "phase": "EARLY_PHASE1", "sponsor": "University of Arizona", "conditions": "Pancreatic Cancer; Colorectal Cancer; Hepatocellular Carcinoma", "interventions": "GLP1-RA (semaglutide)", "enrollment": "30", "startDate": "2026-07-10", "completionDate": "2028-06-30", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07627191" }, { "nctId": "NCT07349641", "title": "A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer", "status": "Not yet recruiting", "phase": "PHASE2", "sponsor": "National Cancer Institute (NCI)", "conditions": "Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma", "interventions": "Medical Device Usage and Evaluation; Tirzepatide", "enrollment": "55", "startDate": "2026-07-06", "completionDate": "2028-12-31", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07349641" }, { "nctId": "NCT07677995", "title": "Free Fatty Acid Effects In Type 2 Diabetes", "status": "Enrolling by invitation", "phase": "NA", "sponsor": "University of Ulster", "conditions": "Type 2 Diabetes; Cardiovascular Disease; Omega-3 Fatty Acids", "interventions": "Omega-3 Fatty Acids; Semaglutide 0.25 mg; Placebo", "enrollment": "60", "startDate": "2026-07", "completionDate": "2026-12", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07677995" }, { "nctId": "NCT07563699", "title": "Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus", "status": "Not yet recruiting", "phase": "PHASE1/PHASE2", "sponsor": "Mapi Pharma Ltd.", "conditions": "Diabete Type 2", "interventions": "SG Depot 2 mg; SG Depot 4 mg; SG Depot 6 mg; SG Depot 8 mg", "enrollment": "24", "startDate": "2026-07", "completionDate": "2028-04", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07563699" }, { "nctId": "NCT07430059", "title": "Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant", "status": "Not yet recruiting", "phase": "PHASE1", "sponsor": "Vivani Medical, Inc", "conditions": "Obesity & Overweight", "interventions": "Semaglutide Implant (NPM-139); Semaglutide (Wegovy) weekly injection", "enrollment": "20", "startDate": "2026-07", "completionDate": "2026-12", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07430059" }, { "nctId": "NCT07573163", "title": "Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion", "status": "Not yet recruiting", "phase": "PHASE2", "sponsor": "Alaa Sada", "conditions": "Mild Autonomous Cortisol Secretion (MACS); Adrenalectomy; Status", "interventions": "Tirzepatide; Standard medical treatment", "enrollment": "34", "startDate": "2026-07", "completionDate": "2028-07-31", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07573163" }, { "nctId": "NCT07613307", "title": "A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting", "status": "Not yet recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocrine System Diseases; Feeding Behavior; Behavior; Fasting; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide Receptors; Receptors, G-Protein-Coupled; Receptors, Cell Surface; Membrane Proteins; Proteins; Receptors, Peptide", "interventions": "Orforglipron", "enrollment": "130", "startDate": "2026-07", "completionDate": "2027-05", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT07613307" }, { "nctId": "NCT07357766", "title": "A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight", "status": "Withdrawn", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Overweight; Obesity", "interventions": "Cagrisema; Placebo CagriSema", "enrollment": "0", "startDate": "2026-06-22", "completionDate": "2027-11-29", "hasResults": "no", "compounds": "semaglutide; cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07357766" }, { "nctId": "NCT07382024", "title": "Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation", "status": "Not yet recruiting", "phase": "NA", "sponsor": "National Taiwan University Hospital", "conditions": "Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight", "interventions": "Tirzepatide; Standard Care (in control arm)", "enrollment": "200", "startDate": "2026-06-16", "completionDate": "2027-12-31", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07382024" }, { "nctId": "NCT07021937", "title": "Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity", "status": "Not yet recruiting", "phase": "PHASE3", "sponsor": "University of Colorado, Denver", "conditions": "Obesity/Therapy", "interventions": "Semaglutide 1.7mg subcutaneous; Placebo", "enrollment": "120", "startDate": "2026-06-15", "completionDate": "2031-04-30", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07021937" }, { "nctId": "NCT07673900", "title": "Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Terrestrial Bio, Inc.", "conditions": "Overweight and/or Obesity", "interventions": "VX-201; semaglutide SC", "enrollment": "62", "startDate": "2026-06-15", "completionDate": "2027-02-10", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07673900" }, { "nctId": "NCT07046819", "title": "Tirzepatide in MetALD", "status": "Recruiting", "phase": "PHASE2", "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", "conditions": "Metabolic Alcohol-associated Liver Disease; Alcohol Use Disorder", "interventions": "Tirzepatide; Placebo", "enrollment": "120", "startDate": "2026-06-11", "completionDate": "2026-07-30", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07046819" }, { "nctId": "NCT07639021", "title": "A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "NNC0662-0419; Semaglutide; NNC0662-0419 Placebo; Semaglutide placebo", "enrollment": "230", "startDate": "2026-06-09", "completionDate": "2027-07-12", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07639021" }, { "nctId": "NCT07257484", "title": "Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors", "status": "Recruiting", "phase": "PHASE4", "sponsor": "Weill Medical College of Cornell University", "conditions": "Obesity (Disorder); Breast Cancer", "interventions": "Tirzepatide", "enrollment": "30", "startDate": "2026-06-08", "completionDate": "2027-12-03", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07257484" }, { "nctId": "NCT07444073", "title": "Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock", "status": "Not yet recruiting", "phase": "N/A", "sponsor": "National University of Singapore", "conditions": "Aging; Obesity & Overweight", "interventions": "Not applicable. This is an observational study.", "enrollment": "440", "startDate": "2026-06-01", "completionDate": "2026-12-31", "hasResults": "no", "compounds": "semaglutide; tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07444073" }, { "nctId": "NCT07387796", "title": "Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation", "status": "Recruiting", "phase": "NA", "sponsor": "The University of Texas at Dallas", "conditions": "Drug Discontinuation; Substance Use Disorders; Eating Behavior Changes; Tirzepatide", "interventions": "Discontinuation and Reinitiation of Tirzepatide", "enrollment": "40", "startDate": "2026-06", "completionDate": "2028-02", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07387796" }, { "nctId": "NCT07607587", "title": "Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity; Overweight", "interventions": "Cagrilintide; Placebo (matched to Cagrilintide)", "enrollment": "114", "startDate": "2026-05-29", "completionDate": "2027-11-19", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07607587" }, { "nctId": "NCT07650149", "title": "Genetic, Microbiological and Behavioral Factors in Obesity", "status": "Recruiting", "phase": "N/A", "sponsor": "Jan Kochanowski University", "conditions": "Obesity & Overweight; Obesity; Genetics", "interventions": "genetic polymorphism; gut microbiome", "enrollment": "200", "startDate": "2026-05-23", "completionDate": "2027-05", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07650149" }, { "nctId": "NCT07527910", "title": "A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Regeneron Pharmaceuticals", "conditions": "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)", "interventions": "ALN-PNP; Tirzepatide; Placebo", "enrollment": "204", "startDate": "2026-05-22", "completionDate": "2030-03-15", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07527910" }, { "nctId": "NCT07564414", "title": "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity; Type 2 Diabetes", "interventions": "Cagrisema; Semaglutide", "enrollment": "2500", "startDate": "2026-05-21", "completionDate": "2028-02-23", "hasResults": "no", "compounds": "semaglutide; cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07564414" }, { "nctId": "NCT07559500", "title": "Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)", "status": "Recruiting", "phase": "PHASE1", "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", "conditions": "Alcohol Use Disorder (AUD)", "interventions": "Tirzepatide; Placebo; [11C]raclopride plus drug; [11C]NNC-112", "enrollment": "176", "startDate": "2026-05-20", "completionDate": "2031-12-31", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07559500" }, { "nctId": "NCT07605052", "title": "A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight", "status": "Active not recruiting", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Overweight; Obesity", "interventions": "Cagrilintide B; Cagrilintide D", "enrollment": "50", "startDate": "2026-05-20", "completionDate": "2026-09-03", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07605052" }, { "nctId": "NCT07597018", "title": "A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity; Overweight", "interventions": "Cagrilintide D; Cagrilintide B and placebo semaglutide I", "enrollment": "234", "startDate": "2026-05-18", "completionDate": "2027-05-28", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07597018" }, { "nctId": "NCT07574723", "title": "Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity", "status": "Recruiting", "phase": "NA", "sponsor": "Dasman Diabetes Institute", "conditions": "Obesity", "interventions": "Tirzepatide (Per-label titration); Tirzepatide (Flexible titration)", "enrollment": "68", "startDate": "2026-05-15", "completionDate": "2029-05-15", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07574723" }, { "nctId": "NCT06726577", "title": "TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis", "status": "Recruiting", "phase": "PHASE1/PHASE2", "sponsor": "Talengen Institute of Life Sciences, Shenzhen, P.R. China.", "conditions": "Amyotrophic Lateral Sclerosis", "interventions": "TP04HN106; Saline", "enrollment": "60", "startDate": "2026-05-10", "completionDate": "2027-01", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT06726577" }, { "nctId": "NCT07301437", "title": "RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.", "status": "Not yet recruiting", "phase": "PHASE4", "sponsor": "The Fourth Affiliated Hospital of Zhejiang University School of Medicine", "conditions": "Overweight and Obese Adults", "interventions": "liraglutide monotherapy; liraglutide combined with orlistat", "enrollment": "120", "startDate": "2026-05-01", "completionDate": "2027-08-31", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07301437" }, { "nctId": "NCT07537088", "title": "Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease", "status": "Not yet recruiting", "phase": "PHASE4", "sponsor": "First Affiliated Hospital of Wannan Medical College", "conditions": "T2DM (Type 2 Diabetes Mellitus); CKD - Chronic Kidney Disease", "interventions": "Dulaglutide; SGLT2i; Finerenone", "enrollment": "468", "startDate": "2026-05", "completionDate": "2027-04", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07537088" }, { "nctId": "NCT07557953", "title": "A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Overweight; Obesity", "interventions": "Cagrilintide; Placebo Cagrilintide", "enrollment": "120", "startDate": "2026-04-30", "completionDate": "2027-04-13", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07557953" }, { "nctId": "NCT07497399", "title": "Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Johns Hopkins University", "conditions": "Multiple Sclerosis", "interventions": "NLY01; Placebo", "enrollment": "120", "startDate": "2026-04-28", "completionDate": "2030-01", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT07497399" }, { "nctId": "NCT07653412", "title": "Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.", "status": "Recruiting", "phase": "N/A", "sponsor": "National and Kapodistrian University of Athens", "conditions": "Obesity (Disorder); Anti-obesity Agents; Precision Medicine", "interventions": "Semaglutide or Tirzepatide", "enrollment": "220", "startDate": "2026-04-22", "completionDate": "2027-01-30", "hasResults": "no", "compounds": "semaglutide; tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07653412" }, { "nctId": "NCT07415954", "title": "A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Novo Nordisk A/S", "conditions": "Diabetes Mellitus, Type 2", "interventions": "NNC0662-0419; Semaglutide; Placebo", "enrollment": "270", "startDate": "2026-04-17", "completionDate": "2027-09-03", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07415954" }, { "nctId": "NCT07527195", "title": "Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "enrollment": "100", "startDate": "2026-04-10", "completionDate": "2028-04-28", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07527195" }, { "nctId": "NCT07107334", "title": "A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia", "status": "Recruiting", "phase": "PHASE2", "sponsor": "University of Florida", "conditions": "Endometrioid Endometrial Adenocarcinoma", "interventions": "Glucagon-like peptide 1 receptor agonist", "enrollment": "20", "startDate": "2026-04-07", "completionDate": "2028-11", "hasResults": "no", "compounds": "liraglutide; orforglipron", "url": "https://clinicaltrials.gov/study/NCT07107334" }, { "nctId": "NCT07446998", "title": "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Veru Inc.", "conditions": "Obesity & Overweight; Mobility Disability; HOMA-IR", "interventions": "Enobosarm; Semaglutide (Wegovy) weekly injection", "enrollment": "200", "startDate": "2026-03-26", "completionDate": "2027-10", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07446998" }, { "nctId": "NCT07463846", "title": "A Study to Evaluate ALN-2232 in Participants With Obesity", "status": "Recruiting", "phase": "PHASE1/PHASE2", "sponsor": "Alnylam Pharmaceuticals", "conditions": "Obesity", "interventions": "ALN-2232; Placebo; Tirzepatide", "enrollment": "156", "startDate": "2026-03-02", "completionDate": "2027-04-27", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07463846" }, { "nctId": "NCT07685834", "title": "Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss", "status": "Active not recruiting", "phase": "NA", "sponsor": "Sofwave Medical LTD", "conditions": "Lax Skin", "interventions": "SUPERB", "enrollment": "30", "startDate": "2026-02-27", "completionDate": "2027-03-01", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07685834" }, { "nctId": "NCT07467447", "title": "Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Hudson Biotech", "conditions": "Obesity", "interventions": "Retatrutide (LY3437943); Placebo; Standardized diet and physical activity counseling throughout the study.", "enrollment": "300", "startDate": "2026-02-15", "completionDate": "2027-03-14", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT07467447" }, { "nctId": "NCT06836284", "title": "The Evira Study: Additional Support During Obesity Treatment", "status": "Recruiting", "phase": "NA", "sponsor": "Karolinska Institutet", "conditions": "Childhood Obesity; Treatment Adherence", "interventions": "Digi-physical treatment tool, Evira; Obesity medication with liraglutide or semaglutide", "enrollment": "40", "startDate": "2026-02-13", "completionDate": "2027-04-01", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT06836284" }, { "nctId": "NCT07619508", "title": "Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.", "status": "Completed", "phase": "N/A", "sponsor": "Brigham and Women's Hospital", "conditions": "Obesity; Overweight", "interventions": "Tirzepatide; Semaglutide", "enrollment": "100000", "startDate": "2026-02-10", "completionDate": "2026-06-01", "hasResults": "no", "compounds": "semaglutide; tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07619508" }, { "nctId": "NCT07411560", "title": "A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Overweight; Obese", "interventions": "Glucose-dependent Insulinotropic Polypeptide (GIP); Cagrilintide; Placebo GIP", "enrollment": "100", "startDate": "2026-02-09", "completionDate": "2027-01-26", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07411560" }, { "nctId": "NCT07417631", "title": "Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.", "status": "Completed", "phase": "N/A", "sponsor": "Brigham and Women's Hospital", "conditions": "Type 2 Diabetes", "interventions": "Dulaglutide; Sitagliptin", "enrollment": "300000", "startDate": "2026-02-03", "completionDate": "2026-06-15", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07417631" }, { "nctId": "NCT07417618", "title": "INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)", "status": "Completed", "phase": "N/A", "sponsor": "Brigham and Women's Hospital", "conditions": "Type 2 Diabetes; Overweight; ASCVD", "interventions": "Dulaglutide; Semaglutide; Tirzepatide; Sitagliptin", "enrollment": "60000", "startDate": "2026-01-27", "completionDate": "2026-06-19", "hasResults": "no", "compounds": "semaglutide; tirzepatide; dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07417618" }, { "nctId": "NCT07390110", "title": "Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)", "status": "Active not recruiting", "phase": "N/A", "sponsor": "Brigham and Women's Hospital", "conditions": "Type 2 Diabetes; Heart Failure", "interventions": "Oral semaglutide; Sitagliptin", "enrollment": "25664", "startDate": "2026-01-24", "completionDate": "2026-06-30", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07390110" }, { "nctId": "NCT07357415", "title": "A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "Retatrutide", "enrollment": "600", "startDate": "2026-01-24", "completionDate": "2028-10", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT07357415" }, { "nctId": "NCT07619495", "title": "Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk", "status": "Completed", "phase": "N/A", "sponsor": "Brigham and Women's Hospital", "conditions": "Type 2 Diabetes Mellitus; Obesity; Overweight", "interventions": "Semaglutide; Dulaglutide", "enrollment": "120000", "startDate": "2026-01-20", "completionDate": "2026-06-01", "hasResults": "no", "compounds": "semaglutide; dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07619495" }, { "nctId": "NCT07347080", "title": "A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus", "status": "Recruiting", "phase": "EARLY_PHASE1", "sponsor": "The First Affiliated Hospital of Henan University of Science and Technology", "conditions": "T2DM", "interventions": "Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））", "enrollment": "9", "startDate": "2026-01-20", "completionDate": "2026-08-31", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT07347080" }, { "nctId": "NCT07253285", "title": "A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Overweight; Obesity", "interventions": "Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "enrollment": "460", "startDate": "2026-01-08", "completionDate": "2030-03-20", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07253285" }, { "nctId": "NCT07640139", "title": "Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes", "status": "Enrolling by invitation", "phase": "N/A", "sponsor": "Indiana University", "conditions": "Obesity", "interventions": "Incretin-based therapies (GLP-1 and GLP-1/GIP)", "enrollment": "125000", "startDate": "2026-01-01", "completionDate": "2029-12-31", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07640139" }, { "nctId": "NCT07313813", "title": "A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus", "status": "Active not recruiting", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes Mellitus (T2DM)", "interventions": "Dulaglutide", "enrollment": "20", "startDate": "2025-12-29", "completionDate": "2026-08", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07313813" }, { "nctId": "NCT07282041", "title": "Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis", "status": "Recruiting", "phase": "PHASE2/PHASE3", "sponsor": "National University of Singapore", "conditions": "Intracranial Atherosclerosis; Stroke, Ischemic", "interventions": "Dulaglutide", "enrollment": "130", "startDate": "2025-12-17", "completionDate": "2030-12-01", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07282041" }, { "nctId": "NCT07276763", "title": "Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention", "status": "Not yet recruiting", "phase": "N/A", "sponsor": "Fudan University", "conditions": "Gastric Retention", "interventions": "No Intervention: Observational Cohort", "enrollment": "16509", "startDate": "2025-12-10", "completionDate": "2025-12-15", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07276763" }, { "nctId": "NCT07241390", "title": "A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease", "interventions": "Orforglipron; Placebo", "enrollment": "7140", "startDate": "2025-12-01", "completionDate": "2031-08", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT07241390" }, { "nctId": "NCT07247084", "title": "A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)", "status": "Recruiting", "phase": "PHASE4", "sponsor": "Eli Lilly and Company", "conditions": "Obesity", "interventions": "Tirzepatide; Standard of Care", "enrollment": "3000", "startDate": "2025-11-24", "completionDate": "2029-07", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07247084" }, { "nctId": "NCT07232719", "title": "A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "Retatrutide; Placebo", "enrollment": "250", "startDate": "2025-11-17", "completionDate": "2027-07", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT07232719" }, { "nctId": "NCT06935838", "title": "Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV", "status": "Completed", "phase": "PHASE2", "sponsor": "University of Hawaii", "conditions": "Obesity and Overweight; HIV; Chronic Inflammation", "interventions": "Tirzepatide", "enrollment": "12", "startDate": "2025-11-12", "completionDate": "2026-06-02", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06935838" }, { "nctId": "NCT07225816", "title": "Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Liraglutide; Oral Semaglutide; Semaglutide", "enrollment": "75", "startDate": "2025-11-07", "completionDate": "2026-06-19", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07225816" }, { "nctId": "NCT07220642", "title": "Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity; Overweight", "interventions": "Cagrilintide; Placebo", "enrollment": "300", "startDate": "2025-11-05", "completionDate": "2027-05-11", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07220642" }, { "nctId": "NCT07220759", "title": "Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Overweight; Obesity; Type 2 Diabetes", "interventions": "Cagrilintide; Placebo (matched to Cagrilintide)", "enrollment": "330", "startDate": "2025-11-05", "completionDate": "2027-05-12", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07220759" }, { "nctId": "NCT07223593", "title": "Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Peripheral Arterial Disease", "interventions": "Orforglipron; Placebo", "enrollment": "1205", "startDate": "2025-10-31", "completionDate": "2028-06", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT07223593" }, { "nctId": "NCT07165028", "title": "A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Metabolic Dysfunction-Associated Steatotic Liver Disease", "interventions": "Tirzepatide; Retatrutide; Placebo", "enrollment": "4500", "startDate": "2025-10-15", "completionDate": "2030-08", "hasResults": "no", "compounds": "tirzepatide; retatrutide", "url": "https://clinicaltrials.gov/study/NCT07165028" }, { "nctId": "NCT07156539", "title": "A Phase 3 Study of HS-20094 in Patients With T2DM", "status": "Not yet recruiting", "phase": "PHASE3", "sponsor": "Jiangsu Hansoh Pharmaceutical Co., Ltd.", "conditions": "Type 2 Diabetes", "interventions": "HS-20094 Injection; Dulaglutide Injection", "enrollment": "546", "startDate": "2025-09-30", "completionDate": "2027-03-30", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07156539" }, { "nctId": "NCT07202884", "title": "A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Urinary Incontinence,Stress", "interventions": "Orforglipron; Placebo", "enrollment": "1000", "startDate": "2025-09-30", "completionDate": "2028-03", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT07202884" }, { "nctId": "NCT07184086", "title": "A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "CagriSema (Cagrilintide B + semaglutide I); Low Energy Diet", "enrollment": "80", "startDate": "2025-09-26", "completionDate": "2027-10-12", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07184086" }, { "nctId": "NCT06727331", "title": "Study of Tirzepatide for Recovery and Alcohol Use Management", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Brigham and Women's Hospital", "conditions": "Alcohol Use Disorder (AUD)", "interventions": "Tirzepatide; Saline Placebo", "enrollment": "20", "startDate": "2025-09-15", "completionDate": "2027-03-01", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06727331" }, { "nctId": "NCT07188545", "title": "Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)", "status": "Active not recruiting", "phase": "N/A", "sponsor": "Ohio State University", "conditions": "Cardiovascular Kidney Metabolic Syndrome", "interventions": "Intervention; Active Comparator", "enrollment": "23280000", "startDate": "2025-09-15", "completionDate": "2029-06-30", "hasResults": "no", "compounds": "dulaglutide; exenatide", "url": "https://clinicaltrials.gov/study/NCT07188545" }, { "nctId": "NCT07153471", "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Osteoarthritis", "interventions": "Orforglipron; Placebo", "enrollment": "800", "startDate": "2025-09-15", "completionDate": "2028-04", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT07153471" }, { "nctId": "NCT07112872", "title": "A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes", "status": "Active not recruiting", "phase": "PHASE2", "sponsor": "Hoffmann-La Roche", "conditions": "Type 2 Diabetes Mellitus", "interventions": "RO7795081; Semaglutide; Placebo", "enrollment": "240", "startDate": "2025-08-19", "completionDate": "2026-11-27", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07112872" }, { "nctId": "NCT07091500", "title": "Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity", "status": "Recruiting", "phase": "NA", "sponsor": "Washington University School of Medicine", "conditions": "Obesity; Skeletal Muscle; Brain Connectivity", "interventions": "Exercise training; Semaglutide; Therapy Cessation", "enrollment": "40", "startDate": "2025-08-11", "completionDate": "2028-08-01", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07091500" }, { "nctId": "NCT07319286", "title": "Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus", "status": "Enrolling by invitation", "phase": "PHASE1/PHASE2", "sponsor": "Ain Shams University", "conditions": "Menstrual Irregularities; Type1 Diabetes Mellitus; Glucagon-Like Peptide-1 Receptor Agonists; Female Reproductive Health", "interventions": "Dulaglutide", "enrollment": "50", "startDate": "2025-08-04", "completionDate": "2026-12", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07319286" }, { "nctId": "NCT06903923", "title": "Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy", "status": "Recruiting", "phase": "PHASE2", "sponsor": "University of Virginia", "conditions": "Obesity in Children; Bone Strength; GLP - 1; Lifestyle Modification; Bone Density; Obesity", "interventions": "GLP-1 receptor agonist; Lifestyle intervention", "enrollment": "120", "startDate": "2025-07-31", "completionDate": "2030-02-28", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT06903923" }, { "nctId": "NCT06937099", "title": "Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Crohn's Disease; Obesity or Overweight", "interventions": "Mirikizumab; Mirikizumab; Tirzepatide; Placebo", "enrollment": "290", "startDate": "2025-06-26", "completionDate": "2028-05", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06937099" }, { "nctId": "NCT06937086", "title": "Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Ulcerative Colitis; Obesity or Overweight", "interventions": "Mirikizumab; Mirikizumab; Tirzepatide; Placebo", "enrollment": "350", "startDate": "2025-06-26", "completionDate": "2028-04", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06937086" }, { "nctId": "NCT07225829", "title": "A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis", "status": "Recruiting", "phase": "PHASE2", "sponsor": "4Moving Biotech", "conditions": "Knee Osteoarthritis; Synovitis of Knee", "interventions": "4P004; Placebo (NaCl 0.9%)", "enrollment": "129", "startDate": "2025-06-17", "completionDate": "2026-07", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07225829" }, { "nctId": "NCT07010432", "title": "The Role of the Amylin Analogue Cagrilintide in Bone Metabolism", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "enrollment": "144", "startDate": "2025-06-12", "completionDate": "2028-05-03", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07010432" }, { "nctId": "NCT06982846", "title": "A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes Mellitus", "interventions": "Retatrutide; Placebo", "enrollment": "80", "startDate": "2025-06-06", "completionDate": "2026-05-04", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06982846" }, { "nctId": "NCT07011667", "title": "A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)", "enrollment": "609", "startDate": "2025-06-03", "completionDate": "2027-03-01", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT07011667" }, { "nctId": "NCT06982859", "title": "A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Diabetes Mellitus; Insulin Sensitivity", "interventions": "Retatrutide; Semaglutide; Placebo", "enrollment": "95", "startDate": "2025-06-02", "completionDate": "2026-11", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06982859" }, { "nctId": "NCT07035093", "title": "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight; Chronic Low Back Pain (CLBP)", "interventions": "Retatrutide; Placebo", "enrollment": "586", "startDate": "2025-05-29", "completionDate": "2027-09", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT07035093" }, { "nctId": "NCT06851962", "title": "Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.", "status": "Active not recruiting", "phase": "PHASE4", "sponsor": "Fundación para la Investigación del Hospital Clínico de Valencia", "conditions": "Diabetes Mellitus Type 2", "interventions": "Metformin; Dulaglutide; Semaglutide 1.0 mg; Empagliflozin (BI 10773); Canagliflozin; Dapagliflozin; pioglitazone; Sitagliptin; Vildagliptin (Galvus); linagliptin", "enrollment": "504", "startDate": "2025-05-26", "completionDate": "2026-06-30", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT06851962" }, { "nctId": "NCT07094568", "title": "Tirzepatide vs Liraglutide in Bone", "status": "Recruiting", "phase": "N/A", "sponsor": "National and Kapodistrian University of Athens", "conditions": "Obesity (Disorder)", "interventions": "", "enrollment": "72", "startDate": "2025-05-23", "completionDate": "2026-12-30", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07094568" }, { "nctId": "NCT06972472", "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight; Type 2 Diabetes", "interventions": "Orforglipron; Placebo", "enrollment": "600", "startDate": "2025-05-19", "completionDate": "2027-08", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06972472" }, { "nctId": "NCT06993792", "title": "A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight; Type 2 Diabetes", "interventions": "Orforglipron; Placebo", "enrollment": "1200", "startDate": "2025-05-15", "completionDate": "2027-08", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06993792" }, { "nctId": "NCT06972459", "title": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "Orforglipron; Placebo", "enrollment": "600", "startDate": "2025-05-15", "completionDate": "2027-08", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06972459" }, { "nctId": "NCT06937203", "title": "A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus", "status": "Recruiting", "phase": "PHASE1/PHASE2", "sponsor": "Arrowhead Pharmaceuticals", "conditions": "Obesity; Diabetes Mellitus, Type 2", "interventions": "ARO-ALK7; Placebo", "enrollment": "150", "startDate": "2025-05-09", "completionDate": "2027-02", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06937203" }, { "nctId": "NCT07029009", "title": "Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Mansa", "conditions": "Maturity Onset Diabetes of the Young", "interventions": "Liraglutide", "enrollment": "50", "startDate": "2025-05-08", "completionDate": "2026-08", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07029009" }, { "nctId": "NCT07055607", "title": "A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice", "status": "Enrolling by invitation", "phase": "N/A", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Semaglutide", "enrollment": "1250", "startDate": "2025-05-01", "completionDate": "2028-08-15", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT07055607" }, { "nctId": "NCT07109700", "title": "A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.", "conditions": "Type 2 Diabetes", "interventions": "HDM1005 1; HDM1005 2; HDM1005 3; HDM1005 4; Placebo; Dulaglutide 1.5 MG", "enrollment": "216", "startDate": "2025-04-30", "completionDate": "2026-01-31", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07109700" }, { "nctId": "NCT06948435", "title": "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Hypertension; Overweight or Obesity", "interventions": "Orforglipron; Placebo", "enrollment": "487", "startDate": "2025-04-30", "completionDate": "2027-09", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06948435" }, { "nctId": "NCT06948422", "title": "A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Hypertension", "interventions": "Orforglipron; Placebo", "enrollment": "974", "startDate": "2025-04-30", "completionDate": "2027-09", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06948422" }, { "nctId": "NCT06952530", "title": "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Hypertension", "interventions": "Orforglipron; Placebo", "enrollment": "487", "startDate": "2025-04-30", "completionDate": "2027-09", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06952530" }, { "nctId": "NCT06897475", "title": "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "LY3457263; Placebo", "enrollment": "240", "startDate": "2025-03-28", "completionDate": "2026-12", "hasResults": "no", "compounds": "semaglutide; tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06897475" }, { "nctId": "NCT06893211", "title": "Effect of Tirzepatide on Brown Adipose Tissue in Obesity", "status": "Completed", "phase": "PHASE2", "sponsor": "University Medical Centre Ljubljana", "conditions": "Obesity", "interventions": "Tirzepatide; Placebo", "enrollment": "34", "startDate": "2025-03-18", "completionDate": "2025-11-29", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06893211" }, { "nctId": "NCT06864026", "title": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)", "status": "Recruiting", "phase": "PHASE4", "sponsor": "Eli Lilly and Company", "conditions": "Psoriatic Arthritis; Overweight or Obesity", "interventions": "Tirzepatide", "enrollment": "200", "startDate": "2025-03-06", "completionDate": "2027-11", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06864026" }, { "nctId": "NCT06859268", "title": "A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity", "interventions": "Retatrutide; Placebo", "enrollment": "643", "startDate": "2025-03-05", "completionDate": "2028-04", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06859268" }, { "nctId": "NCT06824051", "title": "A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "Orforglipron; Placebo", "enrollment": "120", "startDate": "2025-02-17", "completionDate": "2026-01-26", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06824051" }, { "nctId": "NCT06780449", "title": "A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "enrollment": "400", "startDate": "2025-02-10", "completionDate": "2028-08-28", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06780449" }, { "nctId": "NCT06808802", "title": "To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "Retatrutide; Metoprolol", "enrollment": "30", "startDate": "2025-02-03", "completionDate": "2025-04-15", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06808802" }, { "nctId": "NCT06797869", "title": "A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy", "status": "Active not recruiting", "phase": "PHASE2", "sponsor": "Novo Nordisk A/S", "conditions": "Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy", "interventions": "CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)", "enrollment": "142", "startDate": "2025-01-29", "completionDate": "2026-08-21", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06797869" }, { "nctId": "NCT06739122", "title": "A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "Dulaglutide", "enrollment": "55", "startDate": "2025-01-10", "completionDate": "2027-12", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT06739122" }, { "nctId": "NCT07638592", "title": "Tirzepatide-Based Prehabilitation Before Elective Ventral and Incisional Hernia Repair in Patients With Obesity", "status": "Completed", "phase": "N/A", "sponsor": "Azienda Sanitaria Locale Napoli 2 Nord", "conditions": "Obese Adults; Hernia Abdominal Wall; Prehabilitation", "interventions": "Tirzepatide prehabilitation", "enrollment": "91", "startDate": "2025-01-01", "completionDate": "2026-06-01", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT07638592" }, { "nctId": "NCT07325435", "title": "Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists", "status": "Active not recruiting", "phase": "PHASE4", "sponsor": "MaryAnn Banerji", "conditions": "Type 2 Diabetes (T2DM)", "interventions": "SGLT-2 inhibitor; GLP1-RA", "enrollment": "60", "startDate": "2024-12-21", "completionDate": "2027-12-31", "hasResults": "no", "compounds": "liraglutide; dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07325435" }, { "nctId": "NCT05670379", "title": "Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant", "status": "Completed", "phase": "PHASE1", "sponsor": "Vivani Medical, Inc", "conditions": "Overweight and Obesity; Type2diabetes", "interventions": "Exenatide Implant; Bydureon BCise (exenatide extended release); Semaglutide, 1.0 mg/mL", "enrollment": "24", "startDate": "2024-12-20", "completionDate": "2025-08-21", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT05670379" }, { "nctId": "NCT06704763", "title": "A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "Orforglipron; Midazolam; Quinidine", "enrollment": "27", "startDate": "2024-12-06", "completionDate": "2025-02-05", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06704763" }, { "nctId": "NCT06700538", "title": "A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus", "status": "Recruiting", "phase": "PHASE1/PHASE2", "sponsor": "Arrowhead Pharmaceuticals", "conditions": "Obesity", "interventions": "ARO-INHBE; Placebo; Tirzepatide", "enrollment": "180", "startDate": "2024-12-04", "completionDate": "2027-09-17", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06700538" }, { "nctId": "NCT06716307", "title": "A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity", "status": "Completed", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "CagriSema (cagrilintide B and semaglutide I); CagriSema A", "enrollment": "18", "startDate": "2024-12-02", "completionDate": "2025-03-28", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06716307" }, { "nctId": "NCT07370922", "title": "Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia", "status": "Completed", "phase": "PHASE2", "sponsor": "Ain Shams University", "conditions": "Transfusion Dependent Beta Thalassemia", "interventions": "Dulaglutide 0.75Mg/0.5Ml Inj Pen; control group (insulin)", "enrollment": "80", "startDate": "2024-11-22", "completionDate": "2025-11-22", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07370922" }, { "nctId": "NCT06672939", "title": "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "Orforglipron; Placebo", "enrollment": "150", "startDate": "2024-11-18", "completionDate": "2027-12", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06672939" }, { "nctId": "NCT06672549", "title": "A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "Orforglipron; Placebo", "enrollment": "125", "startDate": "2024-11-18", "completionDate": "2027-02", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06672549" }, { "nctId": "NCT06534411", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Diabetes Mellitus, Type 2", "interventions": "Cagrilintide; Semaglutide; Tirzepatide", "enrollment": "1023", "startDate": "2024-11-05", "completionDate": "2026-06-02", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06534411" }, { "nctId": "NCT06662383", "title": "A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity", "interventions": "Retatrutide; Tirzepatide", "enrollment": "800", "startDate": "2024-11-01", "completionDate": "2026-12", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06662383" }, { "nctId": "NCT06779929", "title": "Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes", "status": "Completed", "phase": "N/A", "sponsor": "Brigham and Women's Hospital", "conditions": "Type 2 Diabetes", "interventions": "Tirzepatide; Dulaglutide; Semaglutide", "enrollment": "70000", "startDate": "2024-11-01", "completionDate": "2025-12-01", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT06779929" }, { "nctId": "NCT06649045", "title": "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "OSA; Overweight or Obesity", "interventions": "Orforglipron; Placebo", "enrollment": "600", "startDate": "2024-10-22", "completionDate": "2026-11", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06649045" }, { "nctId": "NCT06888167", "title": "Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.", "status": "Recruiting", "phase": "NA", "sponsor": "Azienda Ospedaliero-Universitaria di Parma", "conditions": "Healthy Volunteer", "interventions": "Study setting", "enrollment": "40", "startDate": "2024-10-14", "completionDate": "2025-12-31", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT06888167" }, { "nctId": "NCT06500143", "title": "Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery", "status": "Completed", "phase": "N/A", "sponsor": "Ciusss de L'Est de l'Île de Montréal", "conditions": "Gastric Retention", "interventions": "Gastric ultrasound", "enrollment": "94", "startDate": "2024-10-09", "completionDate": "2025-02-28", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT06500143" }, { "nctId": "NCT05202353", "title": "A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver", "status": "Recruiting", "phase": "PHASE1", "sponsor": "Boehringer Ingelheim", "conditions": "Obesity", "interventions": "BI 456906; Semaglutide", "enrollment": "30", "startDate": "2024-10-01", "completionDate": "2026-12-02", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT05202353" }, { "nctId": "NCT07096063", "title": "Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk", "status": "Completed", "phase": "N/A", "sponsor": "Brigham and Women's Hospital", "conditions": "Type 2 Diabetes; Overweight; Cardiovascular (CV) Risk", "interventions": "Tirzepatide; Dulaglutide; Semaglutide; Sitagliptin", "enrollment": "887132", "startDate": "2024-10-01", "completionDate": "2025-07-15", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07096063" }, { "nctId": "NCT07088718", "title": "Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data", "status": "Completed", "phase": "N/A", "sponsor": "Brigham and Women's Hospital", "conditions": "Type 2 Diabetes; Major Adverse Cardiac Events; Cardiovascular (CV) Risk", "interventions": "Tirzepatide; Dulaglutide", "enrollment": "44671", "startDate": "2024-10-01", "completionDate": "2025-07-30", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT07088718" }, { "nctId": "NCT06588283", "title": "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Psoriasis; Obesity", "interventions": "Ixekizumab; Tirzepatide", "enrollment": "281", "startDate": "2024-09-30", "completionDate": "2026-01-08", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06588283" }, { "nctId": "NCT05663515", "title": "A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs", "status": "Recruiting", "phase": "N/A", "sponsor": "AstraZeneca", "conditions": "Pancreatic Cancer", "interventions": "Exenatide; Non-GLP-1 RA based glucose lowering drugs", "enrollment": "24000", "startDate": "2024-09-30", "completionDate": "2026-10-01", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT05663515" }, { "nctId": "NCT06640972", "title": "Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists", "status": "Completed", "phase": "PHASE2", "sponsor": "Response Pharmaceuticals", "conditions": "Triglycerides; Weight Gain Trajectory; Cholesterol, Elevated", "interventions": "RDX-002; Placebo", "enrollment": "68", "startDate": "2024-09-27", "completionDate": "2025-01-04", "hasResults": "yes", "compounds": "semaglutide; tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06640972" }, { "nctId": "NCT06396416", "title": "Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2", "status": "Recruiting", "phase": "PHASE4", "sponsor": "Western University, Canada", "conditions": "Obesity; Chronic Kidney Disease", "interventions": "Semaglutide; Virtual Weight Management Coaching", "enrollment": "60", "startDate": "2024-09-26", "completionDate": "2026-09-30", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT06396416" }, { "nctId": "NCT06584916", "title": "A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "Orforglipron; Placebo", "enrollment": "376", "startDate": "2024-09-13", "completionDate": "2025-11-21", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06584916" }, { "nctId": "NCT06449235", "title": "Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh", "status": "Not yet recruiting", "phase": "PHASE4", "sponsor": "Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders", "conditions": "Type2diabetes", "interventions": "Omarigliptin; Sulphonylureas; Metformin; Other DPP4-i; Thiazolidinediones; Alpha-Glucosidase Inhibitor; Glucagon-Like Peptide-1; Receptor Agonists (GLP1RA); SGLT2 inhibitors", "enrollment": "938", "startDate": "2024-09", "completionDate": "2025-04", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT06449235" }, { "nctId": "NCT06252623", "title": "Exenatide For Reducing the Reinforcing Effects of Cocaine", "status": "Withdrawn", "phase": "PHASE1", "sponsor": "Christopher D. Verrico", "conditions": "Cocaine Use Disorder", "interventions": "Exenatide; Placebo", "enrollment": "0", "startDate": "2024-08-01", "completionDate": "2026-03-01", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT06252623" }, { "nctId": "NCT06533527", "title": "Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy", "status": "Completed", "phase": "PHASE4", "sponsor": "The Cleveland Clinic", "conditions": "Diabetes Mellitus, Type 2; Obesity; Gastroparesis", "interventions": "GLP-1 medication", "enrollment": "69", "startDate": "2024-07-31", "completionDate": "2025-05-20", "hasResults": "yes", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT06533527" }, { "nctId": "NCT06257966", "title": "A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Beijing Dongfang Biotech Co., Ltd.", "conditions": "Type2 Diabetes Mellitus", "interventions": "Exendin-4 Fc fusion protein injection(1.2mg）; Exendin-4 Fc fusion protein injection（2.4mg）; Dulaglutide; Metformin", "enrollment": "600", "startDate": "2024-07-17", "completionDate": "2026-10-01", "hasResults": "no", "compounds": "dulaglutide; exenatide", "url": "https://clinicaltrials.gov/study/NCT06257966" }, { "nctId": "NCT06254014", "title": "A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Beijing Dongfang Biotech Co., Ltd.", "conditions": "Type 2 Diabetes Mellitus", "interventions": "Exendin-4 Fc fusion protein injection; Exendin-4 Fc fusion protein injection; Placebo", "enrollment": "270", "startDate": "2024-07-10", "completionDate": "2026-05-01", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT06254014" }, { "nctId": "NCT06482411", "title": "Risk Factors Affect Weight Loss Outcomes After Treatment.", "status": "Completed", "phase": "N/A", "sponsor": "E-DA Hospital", "conditions": "Weight Regain", "interventions": "", "enrollment": "3602", "startDate": "2024-06-27", "completionDate": "2025-10-22", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT06482411" }, { "nctId": "NCT06388187", "title": "A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Cagrilintide; Semaglutide; Placebo", "enrollment": "300", "startDate": "2024-06-24", "completionDate": "2026-04-22", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06388187" }, { "nctId": "NCT06439277", "title": "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Weight Gain", "interventions": "Tirzepatide; Placebo", "enrollment": "300", "startDate": "2024-06-03", "completionDate": "2027-10", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06439277" }, { "nctId": "NCT02586831", "title": "Diabetes Islet Preservation Immune Treatment", "status": "Withdrawn", "phase": "PHASE1/PHASE2", "sponsor": "Camillo Ricordi and Jay Skyler", "conditions": "Diabetes Mellitus, Type 1; Hypoglycemia; Autoimmune Diseases; Diabetes Mellitus", "interventions": "Anti-Thymocyte Globulin (ATG); Interleukin 2; Exenatide; Adalimumab; ATG Placebo; IL-2 Placebo; Adalimumab Placebo; Exenatide Placebo", "enrollment": "0", "startDate": "2024-06-01", "completionDate": "2024-06-01", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT02586831" }, { "nctId": "NCT06409130", "title": "Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease", "status": "Completed", "phase": "PHASE2", "sponsor": "Novo Nordisk A/S", "conditions": "Alcohol-related Liver Disease", "interventions": "NNC0194-0499; Semaglutide; NNC0194-0499 placebo; Semaglutide placebo (Group A); Cagrilintide + semaglutide; Cagrilintide; Cagrilintide placebo; Semaglutide placebo (Group B)", "enrollment": "270", "startDate": "2024-05-20", "completionDate": "2025-11-21", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06409130" }, { "nctId": "NCT06403761", "title": "Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes", "status": "Completed", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Diabetes Mellitus, Type 2", "interventions": "Semaglutide; Cagrilintide; Placebo semaglutide; Placebo cagrilintide", "enrollment": "158", "startDate": "2024-05-06", "completionDate": "2025-12-28", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06403761" }, { "nctId": "NCT06383390", "title": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)", "interventions": "Retatrutide; Placebo", "enrollment": "10000", "startDate": "2024-04-30", "completionDate": "2029-02", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06383390" }, { "nctId": "NCT06354660", "title": "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Diabetes Type 2", "interventions": "Retatrutide; Placebo", "enrollment": "537", "startDate": "2024-04-10", "completionDate": "2026-01-22", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06354660" }, { "nctId": "NCT06283641", "title": "Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.", "status": "Completed", "phase": "N/A", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Liraglutide", "enrollment": "300", "startDate": "2024-04-08", "completionDate": "2025-01-13", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT06283641" }, { "nctId": "NCT06235086", "title": "A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus", "status": "Completed", "phase": "PHASE3", "sponsor": "CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.", "conditions": "Type 2 Diabetes Mellitus", "interventions": "TG103; Dulaglutide", "enrollment": "632", "startDate": "2024-04-08", "completionDate": "2026-02-03", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT06235086" }, { "nctId": "NCT06131372", "title": "A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo", "status": "Completed", "phase": "PHASE2", "sponsor": "Novo Nordisk A/S", "conditions": "Chronic Kidney Disease; Type 2 Diabetes; Obesity", "interventions": "Cagrilintide; Semaglutide; Placebo", "enrollment": "626", "startDate": "2024-04-01", "completionDate": "2025-09-24", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06131372" }, { "nctId": "NCT07590219", "title": "Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity", "status": "Active not recruiting", "phase": "PHASE4", "sponsor": "University of Sao Paulo General Hospital", "conditions": "Severe Obesity; Cardiovascular Function; Liraglutide; Childhood Obesity; Echocardiography; Speckle Tracking", "interventions": "Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml", "enrollment": "30", "startDate": "2024-03-30", "completionDate": "2027-04", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07590219" }, { "nctId": "NCT06323161", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Type 2 Diabetes", "interventions": "Cagrilintide; Semaglutide; Placebo", "enrollment": "274", "startDate": "2024-03-26", "completionDate": "2025-09-09", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06323161" }, { "nctId": "NCT06313528", "title": "A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Obesity", "interventions": "LY3437943; Placebo", "enrollment": "85", "startDate": "2024-03-20", "completionDate": "2025-08-26", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06313528" }, { "nctId": "NCT06324461", "title": "GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery", "status": "Recruiting", "phase": "PHASE4", "sponsor": "The University of Hong Kong", "conditions": "Myocardial Injury", "interventions": "Dulaglutide 0.75mg subcutaneous injection", "enrollment": "372", "startDate": "2024-03-20", "completionDate": "2028-12-31", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT06324461" }, { "nctId": "NCT06323174", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Type 2 Diabetes", "interventions": "Cagrilintide; Semaglutide; Placebo", "enrollment": "189", "startDate": "2024-03-19", "completionDate": "2025-10-01", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06323174" }, { "nctId": "NCT06297603", "title": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "Retatrutide; Placebo", "enrollment": "320", "startDate": "2024-03-15", "completionDate": "2026-10", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06297603" }, { "nctId": "NCT06003153", "title": "GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH", "status": "Recruiting", "phase": "PHASE4", "sponsor": "Massachusetts General Hospital", "conditions": "Genetic Predisposition; Metabolic Diseases; Type 2 Diabetes", "interventions": "oral semaglutide; Mixed Meal Tolerance Test (MMTT)", "enrollment": "125", "startDate": "2024-03-12", "completionDate": "2027-05-31", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT06003153" }, { "nctId": "NCT06289504", "title": "A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight", "status": "Completed", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Cagrilintide; Semaglutide; Atorvastatin; Warfarin", "enrollment": "34", "startDate": "2024-02-27", "completionDate": "2024-10-16", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06289504" }, { "nctId": "NCT06207877", "title": "A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight", "status": "Completed", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Cagrilintide; Semaglutide; Placebo", "enrollment": "62", "startDate": "2024-02-23", "completionDate": "2024-10-16", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06207877" }, { "nctId": "NCT06260722", "title": "Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Diabetes Mellitus, Type 2", "interventions": "Retatrutide; Semaglutide", "enrollment": "1250", "startDate": "2024-02-21", "completionDate": "2026-08", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06260722" }, { "nctId": "NCT06267092", "title": "A Study of How CagriSema Works on Appetite in People With Excess Body Weight", "status": "Completed", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Overweight; Obesity", "interventions": "No treatment given; Cagrilintide and Semaglutide; Placebo", "enrollment": "164", "startDate": "2024-02-15", "completionDate": "2025-04-07", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06267092" }, { "nctId": "NCT06901648", "title": "A Study of HS-20094 in Patients With T2DM", "status": "Completed", "phase": "PHASE2", "sponsor": "Jiangsu Hansoh Pharmaceutical Co., Ltd.", "conditions": "Type 2 Diabetes", "interventions": "HS-20094; Dulaglutide; Palcebo", "enrollment": "275", "startDate": "2024-02-06", "completionDate": "2025-03-07", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT06901648" }, { "nctId": "NCT05965908", "title": "Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome", "status": "Completed", "phase": "PHASE3", "sponsor": "Beni-Suef University", "conditions": "Polycystic Ovary", "interventions": "liraglutide; Metformin", "enrollment": "150", "startDate": "2024-01-30", "completionDate": "2025-03-30", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT05965908" }, { "nctId": "NCT06171152", "title": "Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues", "status": "Suspended", "phase": "EARLY_PHASE1", "sponsor": "University of Chicago", "conditions": "Multiple Sclerosis; Long COVID; Long Covid19; Obese; Obesity; Obesity, Morbid; Acute Leukemia in Remission", "interventions": "Liraglutide Pen Injector [Saxenda]; Medication Diary", "enrollment": "30", "startDate": "2024-01-26", "completionDate": "2027-06-01", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT06171152" }, { "nctId": "NCT06221969", "title": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Type 2 Diabetes", "interventions": "Cagrilintide; Semaglutide; Tirzepatide", "enrollment": "1024", "startDate": "2024-01-16", "completionDate": "2026-03-04", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06221969" }, { "nctId": "NCT06192108", "title": "A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "Orforglipron; Dapagliflozin", "enrollment": "962", "startDate": "2024-01-10", "completionDate": "2025-09-26", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06192108" }, { "nctId": "NCT06186622", "title": "A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy; Obese; Overweight", "interventions": "Orforglipron; Simvastatin; Digoxin; Rosuvastatin; Acetaminophen; Midazolam; Sodium Bicarbonate", "enrollment": "50", "startDate": "2024-01-02", "completionDate": "2024-07-10", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06186622" }, { "nctId": "NCT06256419", "title": "Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM", "status": "Recruiting", "phase": "NA", "sponsor": "The Affiliated Hospital of Xuzhou Medical University", "conditions": "Type 2 Diabetes Mellitus; Susceptibility, Genetic", "interventions": "GLP-1 receptor agonist; responders group and nonresponders group", "enrollment": "300", "startDate": "2024-01-01", "completionDate": "2028-01-31", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT06256419" }, { "nctId": "NCT07304141", "title": "Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity", "status": "Completed", "phase": "N/A", "sponsor": "Göteborg University", "conditions": "Obesity (Disorder); Child Obesity", "interventions": "Liraglutide 3 mg (Saxenda)", "enrollment": "128", "startDate": "2023-12-20", "completionDate": "2025-12-12", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07304141" }, { "nctId": "NCT06148649", "title": "Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus", "status": "Completed", "phase": "PHASE2", "sponsor": "Dongguan HEC Biopharmaceutical R&D Co., Ltd.", "conditions": "Type 2 Diabetes", "interventions": "HEC88473, Placebo, Dulaglutide", "enrollment": "234", "startDate": "2023-12-10", "completionDate": "2025-02-27", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT06148649" }, { "nctId": "NCT06131437", "title": "A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Cagrilintide; Semaglutide; Tirzepatide", "enrollment": "809", "startDate": "2023-11-27", "completionDate": "2025-12-08", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06131437" }, { "nctId": "NCT06143956", "title": "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "LY3305677; LY3841136; Tirzepatide; LY3549492; LY3532226; Placebo; Placebo", "enrollment": "1481", "startDate": "2023-11-17", "completionDate": "2027-09", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06143956" }, { "nctId": "NCT06109311", "title": "A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "Orforglipron; Placebo", "enrollment": "546", "startDate": "2023-11-10", "completionDate": "2025-09-15", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06109311" }, { "nctId": "NCT06247748", "title": "Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects", "status": "Completed", "phase": "PHASE1", "sponsor": "Beijing Dongfang Biotech Co., Ltd.", "conditions": "Diabetes Mellitus, Type 2; Overweight", "interventions": "Exendin-4 Fc fusion protein (JY09) injection; Metformin Hydrochloride tablet; Rosuvastatin calcium tablets; Digoxin tablet", "enrollment": "28", "startDate": "2023-10-19", "completionDate": "2024-04-15", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT06247748" }, { "nctId": "NCT06085482", "title": "A Phase I Study of LY3502970 in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "LY3502970; [14C]-LY3502970", "enrollment": "10", "startDate": "2023-10-19", "completionDate": "2024-01-05", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06085482" }, { "nctId": "NCT06015893", "title": "Semaglutide Therapy for Alcohol Reduction (STAR)", "status": "Recruiting", "phase": "PHASE2", "sponsor": "National Institute on Drug Abuse (NIDA)", "conditions": "Addiction; Alcohol Use Disorder", "interventions": "Take Control; Semaglutide", "enrollment": "80", "startDate": "2023-10-17", "completionDate": "2030-12-31", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT06015893" }, { "nctId": "NCT06075667", "title": "A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "Tirzepatide; Placebo", "enrollment": "160", "startDate": "2023-10-16", "completionDate": "2026-06-02", "hasResults": "no", "compounds": "tirzepatide", "url": "https://clinicaltrials.gov/study/NCT06075667" }, { "nctId": "NCT05478707", "title": "Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes", "status": "Suspended", "phase": "PHASE2", "sponsor": "University of Virginia", "conditions": "Diabetes Mellitus, Type 1; Endothelial Dysfunction", "interventions": "Dulaglutide; Placebo", "enrollment": "47", "startDate": "2023-10-05", "completionDate": "2028-06-30", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT05478707" }, { "nctId": "NCT06010004", "title": "A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "Orforglipron", "enrollment": "401", "startDate": "2023-09-28", "completionDate": "2025-06-05", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06010004" }, { "nctId": "NCT06065540", "title": "A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Type 2 Diabetes Mellitus", "interventions": "Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "enrollment": "2734", "startDate": "2023-09-27", "completionDate": "2025-11-19", "hasResults": "no", "compounds": "semaglutide; cagrilintide", "url": "https://clinicaltrials.gov/study/NCT06065540" }, { "nctId": "NCT06045221", "title": "A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "Orforglipron; Semaglutide", "enrollment": "1698", "startDate": "2023-09-22", "completionDate": "2025-08-22", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT06045221" }, { "nctId": "NCT07309094", "title": "Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD", "status": "Recruiting", "phase": "N/A", "sponsor": "Cardenal Herrera University", "conditions": "Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2", "interventions": "GLP-1 receptor agonist; SGLT2 inhibitor; Tirzepatide; Other drugs", "enrollment": "250", "startDate": "2023-09-15", "completionDate": "2027-07-31", "hasResults": "no", "compounds": "liraglutide; dulaglutide; exenatide", "url": "https://clinicaltrials.gov/study/NCT07309094" }, { "nctId": "NCT05569772", "title": "Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes", "status": "Recruiting", "phase": "PHASE3", "sponsor": "Universitaire Ziekenhuizen KU Leuven", "conditions": "Glucose Intolerance After a Recent History of Gestational Diabetes", "interventions": "Semaglutide Pen Injector; Semaglutide placebo", "enrollment": "252", "startDate": "2023-09-14", "completionDate": "2029-06", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT05569772" }, { "nctId": "NCT06039826", "title": "A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Overweight", "interventions": "LY3437943; Ethinyl Estradiol; Drospirenone", "enrollment": "46", "startDate": "2023-09-12", "completionDate": "2024-07-11", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06039826" }, { "nctId": "NCT07374445", "title": "Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery", "status": "Completed", "phase": "PHASE4", "sponsor": "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School", "conditions": "Obesity; Weight Loss; Bariatric Surgery", "interventions": "Liraglutide injection; Diet and exercise guidelines", "enrollment": "100", "startDate": "2023-09-01", "completionDate": "2025-06-01", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07374445" }, { "nctId": "NCT06003465", "title": "A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "LY3437943; Test; Reference", "enrollment": "57", "startDate": "2023-08-29", "completionDate": "2024-02-08", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT06003465" }, { "nctId": "NCT05996848", "title": "A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity or Overweight", "interventions": "Cagrilintide; Semaglutide; Placebo Semaglutide; Placebo Cagrilintide", "enrollment": "300", "startDate": "2023-08-15", "completionDate": "2025-01-06", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT05996848" }, { "nctId": "NCT05971940", "title": "A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "Orforglipron; Placebo", "enrollment": "559", "startDate": "2023-08-09", "completionDate": "2025-04-03", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05971940" }, { "nctId": "NCT05984238", "title": "A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)", "status": "Completed", "phase": "NA", "sponsor": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", "conditions": "Diabetes Mellitus, Type 2", "interventions": "ReCET; Semaglutide, 1.0 mg/mL; Sham procedure", "enrollment": "33", "startDate": "2023-08-03", "completionDate": "2025-03-21", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT05984238" }, { "nctId": "NCT05931367", "title": "A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight; Osteo Arthritis Knee", "interventions": "Retatrutide; Placebo", "enrollment": "445", "startDate": "2023-08-01", "completionDate": "2025-11-14", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05931367" }, { "nctId": "NCT05936151", "title": "A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "status": "Completed", "phase": "PHASE2", "sponsor": "Eli Lilly and Company", "conditions": "Overweight or Obesity; CKD; Type 2 Diabetes", "interventions": "Retatrutide; Placebo", "enrollment": "146", "startDate": "2023-07-20", "completionDate": "2025-10-01", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05936151" }, { "nctId": "NCT05959096", "title": "A Study of LY3437943 in Healthy Participants With a High Body Mass Index", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "LY3437943; LY3437943", "enrollment": "85", "startDate": "2023-07-18", "completionDate": "2024-07-25", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05959096" }, { "nctId": "NCT05916560", "title": "A Study of LY3437943 in Participants With Impaired and Normal Liver Function", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy; Hepatic Insufficiency", "interventions": "LY3437943", "enrollment": "43", "startDate": "2023-07-13", "completionDate": "2025-03-02", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05916560" }, { "nctId": "NCT05936138", "title": "A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Renal Insufficiency; Healthy", "interventions": "LY3502970", "enrollment": "24", "startDate": "2023-07-13", "completionDate": "2024-04-11", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05936138" }, { "nctId": "NCT05929079", "title": "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea", "interventions": "Retatrutide; Placebo", "enrollment": "1000", "startDate": "2023-07-11", "completionDate": "2026-05", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05929079" }, { "nctId": "NCT05929066", "title": "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea", "interventions": "Retatrutide; Placebo", "enrollment": "2335", "startDate": "2023-07-10", "completionDate": "2026-04-06", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05929066" }, { "nctId": "NCT05925959", "title": "Preoperative Weight Loss for Open Abdominal Wall Reconstruction", "status": "Recruiting", "phase": "NA", "sponsor": "Benjamin T. Miller", "conditions": "Abdominal Wall Hernia", "interventions": "Preoperative Weight Management Program", "enrollment": "258", "startDate": "2023-06-19", "completionDate": "2027-06-01", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT05925959" }, { "nctId": "NCT05882032", "title": "A Study of LY3502970 in Participants With Impaired and Normal Liver Function", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy; Hepatic Insufficiency", "interventions": "LY3502970", "enrollment": "29", "startDate": "2023-06-13", "completionDate": "2024-11-18", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05882032" }, { "nctId": "NCT05869903", "title": "A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight; Overweight or Obesity", "interventions": "Orforglipron; Placebo", "enrollment": "3127", "startDate": "2023-06-05", "completionDate": "2025-07-25", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05869903" }, { "nctId": "NCT05872620", "title": "A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight; Type 2 Diabetes", "interventions": "Orforglipron; Placebo", "enrollment": "1613", "startDate": "2023-06-05", "completionDate": "2025-08-08", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05872620" }, { "nctId": "NCT05882045", "title": "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Cardiovascular Diseases", "interventions": "Retatrutide; Placebo", "enrollment": "1946", "startDate": "2023-05-30", "completionDate": "2026-04-16", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05882045" }, { "nctId": "NCT05681299", "title": "Effects of GH and Lirglutide on AgRP", "status": "Recruiting", "phase": "PHASE4", "sponsor": "Columbia University", "conditions": "Healthy; Growth Hormone Deficiency", "interventions": "growth hormone and lirglutide; growth hormone; liraglutide; Placebo", "enrollment": "40", "startDate": "2023-05-01", "completionDate": "2028-04-30", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT05681299" }, { "nctId": "NCT05841238", "title": "A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy; Obese", "interventions": "LY3502970", "enrollment": "52", "startDate": "2023-04-26", "completionDate": "2023-09-14", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05841238" }, { "nctId": "NCT05482789", "title": "Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes", "status": "Recruiting", "phase": "PHASE4", "sponsor": "Maisa N. Feghali, MD", "conditions": "Gestational Diabetes", "interventions": "Exenatide", "enrollment": "13", "startDate": "2023-04-12", "completionDate": "2025-12-31", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT05482789" }, { "nctId": "NCT05564104", "title": "A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body", "status": "Completed", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Hepatic Impairment; Healthy Volunteers", "interventions": "Cagrilintide", "enrollment": "32", "startDate": "2023-04-05", "completionDate": "2024-09-06", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT05564104" }, { "nctId": "NCT05813925", "title": "A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity or Overweight", "interventions": "Cagrilintide; Semaglutide; Placebo Semaglutide", "enrollment": "331", "startDate": "2023-04-03", "completionDate": "2025-01-17", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT05813925" }, { "nctId": "NCT05803421", "title": "A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease", "interventions": "Orforglipron; Insulin Glargine", "enrollment": "2749", "startDate": "2023-04-03", "completionDate": "2026-03-16", "hasResults": "no", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05803421" }, { "nctId": "NCT05669755", "title": "REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Cardiovascular Disease", "interventions": "Cagrilintide; Semaglutide; Placebo", "enrollment": "7101", "startDate": "2023-03-01", "completionDate": "2027-09-01", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT05669755" }, { "nctId": "NCT07340437", "title": "Clinical Study of 18F-Exendin-4 in Insulinoma", "status": "Completed", "phase": "N/A", "sponsor": "Sichuan Provincial People's Hospital", "conditions": "Insulinoma", "interventions": "", "enrollment": "20", "startDate": "2023-02-01", "completionDate": "2025-10-31", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT07340437" }, { "nctId": "NCT05394519", "title": "A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Overweight; Obesity; Type 2 Diabetes Mellitus", "interventions": "Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "enrollment": "1200", "startDate": "2023-02-01", "completionDate": "2025-01-28", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT05394519" }, { "nctId": "NCT05579249", "title": "A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America", "status": "Completed", "phase": "PHASE4", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Semaglutide; Orlistat; Phentermine/Topiramate; Naltrexone/Bupropion; Liraglutide", "enrollment": "500", "startDate": "2023-01-19", "completionDate": "2024-11-27", "hasResults": "yes", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT05579249" }, { "nctId": "NCT05680129", "title": "A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM", "status": "Completed", "phase": "PHASE3", "sponsor": "Hangzhou Sciwind Biosciences Co., Ltd.", "conditions": "T2DM; Type 2 Diabetes Mellitus", "interventions": "Ecnoglutide high dosage; Ecnoglutide low dosage; Dulaglutide; Metformin", "enrollment": "623", "startDate": "2023-01-10", "completionDate": "2024-07-03", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT05680129" }, { "nctId": "NCT05659537", "title": "A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India", "status": "Completed", "phase": "PHASE4", "sponsor": "Eli Lilly and Company", "conditions": "Diabetes Mellitus, Type 2", "interventions": "Dulaglutide", "enrollment": "212", "startDate": "2022-12-29", "completionDate": "2024-01-16", "hasResults": "yes", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT05659537" }, { "nctId": "NCT05610800", "title": "Exenatide for Smoking Cessation and Prevention of Weight Gain", "status": "Completed", "phase": "PHASE2", "sponsor": "The University of Texas Health Science Center, Houston", "conditions": "Smoking Cessation; Weight Gain", "interventions": "Exenatide 2 milligram (mg) Injection; Placebo; Nicotine patch; Smoking Cessation Counseling", "enrollment": "140", "startDate": "2022-12-07", "completionDate": "2025-11-07", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT05610800" }, { "nctId": "NCT05564039", "title": "A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)", "status": "Completed", "phase": "PHASE4", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "Tirzepatide; Dulaglutide", "enrollment": "282", "startDate": "2022-11-30", "completionDate": "2024-07-15", "hasResults": "yes", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT05564039" }, { "nctId": "NCT05598008", "title": "Effects of Glucagon-like-Peptide-1 Analogues on Sexuality", "status": "Completed", "phase": "N/A", "sponsor": "University Hospital, Basel, Switzerland", "conditions": "Sexual Desire", "interventions": "", "enrollment": "85", "startDate": "2022-11-25", "completionDate": "2025-10-24", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT05598008" }, { "nctId": "NCT05347147", "title": "A Trial to Determine the Efficacy and Safety of Presendin in IIH", "status": "Terminated", "phase": "PHASE3", "sponsor": "Invex Therapeutics Ltd.", "conditions": "Idiopathic Intracranial Hypertension", "interventions": "Presendin; Placebo", "enrollment": "14", "startDate": "2022-11-18", "completionDate": "2023-09-18", "hasResults": "yes", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT05347147" }, { "nctId": "NCT05616013", "title": "Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese", "status": "Completed", "phase": "PHASE2", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Obese; Overweight or Obesity", "interventions": "Bimagrumab; Semaglutide; Placebo", "enrollment": "507", "startDate": "2022-11-16", "completionDate": "2024-05-16", "hasResults": "yes", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT05616013" }, { "nctId": "NCT05611957", "title": "A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy; Renal Insufficiency", "interventions": "LY3437943", "enrollment": "29", "startDate": "2022-11-16", "completionDate": "2023-09-05", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05611957" }, { "nctId": "NCT05567796", "title": "A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "enrollment": "3400", "startDate": "2022-11-01", "completionDate": "2024-10-30", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT05567796" }, { "nctId": "NCT05548231", "title": "A Study of LY3437943 in Chinese Participants With Obesity Or Overweight", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Overweight; Obesity", "interventions": "LY3437943; Placebo", "enrollment": "32", "startDate": "2022-10-24", "completionDate": "2023-07-27", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05548231" }, { "nctId": "NCT05573230", "title": "A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "Midazolam; LY3502970; Cyclosporine", "enrollment": "32", "startDate": "2022-10-17", "completionDate": "2023-01-17", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05573230" }, { "nctId": "NCT05313529", "title": "LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes", "status": "Active not recruiting", "phase": "NA", "sponsor": "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School", "conditions": "Type 2 Diabetes Mellitus; Mild Cognitive Impairment", "interventions": "Liraglutide; Empagliflozin; Linagliptin", "enrollment": "396", "startDate": "2022-10-08", "completionDate": "2025-12-31", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT05313529" }, { "nctId": "NCT05390892", "title": "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes", "status": "Recruiting", "phase": "PHASE4", "sponsor": "Brigham and Women's Hospital", "conditions": "Type2Diabetes; ASCVD", "interventions": "SGLT2 inhibitor; GLP-1 receptor agonist", "enrollment": "6000", "startDate": "2022-09-26", "completionDate": "2029-03-01", "hasResults": "no", "compounds": "liraglutide; dulaglutide", "url": "https://clinicaltrials.gov/study/NCT05390892" }, { "nctId": "NCT05371496", "title": "Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction", "status": "Enrolling by invitation", "phase": "PHASE4", "sponsor": "Mayo Clinic", "conditions": "Cardiomyopathy; Heart Failure With Preserved Ejection Fraction (HFpEF); Obesity", "interventions": "Semaglutide; Placebo; Counselling on healthy lifestyle intervention", "enrollment": "81", "startDate": "2022-09-06", "completionDate": "2026-08", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT05371496" }, { "nctId": "NCT05469126", "title": "A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "LY3502970; Clarithromycin", "enrollment": "26", "startDate": "2022-08-01", "completionDate": "2022-11-03", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05469126" }, { "nctId": "NCT05445232", "title": "A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Obesity", "interventions": "LY3437943; Midazolam; Warfarin; Caffeine", "enrollment": "32", "startDate": "2022-07-08", "completionDate": "2023-02-24", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT05445232" }, { "nctId": "NCT05574439", "title": "Young Adults With Early-onset Obesity Treated With Semaglutide", "status": "Completed", "phase": "PHASE4", "sponsor": "Signe Torekov", "conditions": "Obesity, Adolescent", "interventions": "TCOC treatment; Semaglutide 3 mg/ml; Placebo (Semaglutide 3 mg/ml)", "enrollment": "246", "startDate": "2022-05-30", "completionDate": "2026-04-01", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT05574439" }, { "nctId": "NCT05313802", "title": "A Study of LY3502970 in Healthy Overweight and Obese Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy; Obese", "interventions": "LY3502970", "enrollment": "72", "startDate": "2022-05-26", "completionDate": "2022-09-09", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05313802" }, { "nctId": "NCT05356104", "title": "GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)", "status": "Recruiting", "phase": "PHASE2", "sponsor": "Chinese University of Hong Kong", "conditions": "Cerebral Small Vessel Disease", "interventions": "GLP-1 receptor agonist", "enrollment": "110", "startDate": "2022-05-25", "completionDate": "2027-05", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT05356104" }, { "nctId": "NCT05341089", "title": "A Study of Two Different Formulations of LY3502970 in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "LY3502970", "enrollment": "39", "startDate": "2022-05-17", "completionDate": "2022-09-01", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05341089" }, { "nctId": "NCT04873245", "title": "Lifestyle Counseling and Medication for Adolescent Weight Management", "status": "Completed", "phase": "PHASE2", "sponsor": "University of Minnesota", "conditions": "Obesity, Childhood", "interventions": "Intensive Behavioral Program; Semaglutide and Behavioral Program", "enrollment": "120", "startDate": "2022-03-15", "completionDate": "2026-06-29", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT04873245" }, { "nctId": "NCT05254418", "title": "Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease", "status": "Completed", "phase": "PHASE2", "sponsor": "Vanderbilt University Medical Center", "conditions": "Chronic Kidney Diseases", "interventions": "dulaglutide injection", "enrollment": "7", "startDate": "2022-03-15", "completionDate": "2024-05-01", "hasResults": "yes", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT05254418" }, { "nctId": "NCT05662189", "title": "Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus", "status": "Recruiting", "phase": "NA", "sponsor": "Azienda Ospedaliero-Universitaria di Parma", "conditions": "Type1diabetes; Type2diabetes; Pre Diabetes; Hyperinsulinism", "interventions": "68Ga-exendin-4; mixed meal test", "enrollment": "70", "startDate": "2022-03-15", "completionDate": "2025-07", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT05662189" }, { "nctId": "NCT07539584", "title": "Adiponectin in Patients With Metabolic Disorders", "status": "Completed", "phase": "NA", "sponsor": "Moscow Regional Research and Clinical Institute (MONIKI)", "conditions": "Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Type 2 Diabetes Mellitus (T2DM)", "interventions": "SGLT2 inhibitor; GLP-1 RA", "enrollment": "130", "startDate": "2022-03-01", "completionDate": "2024-04-08", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT07539584" }, { "nctId": "NCT04307797", "title": "Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes", "status": "Completed", "phase": "PHASE4", "sponsor": "Cambridge University Hospitals NHS Foundation Trust", "conditions": "Type 2 Diabetes; Obesity", "interventions": "0.9% Sodium-chloride; Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min; Glucagon 12.5ng/kg/min and 0.9% saline; 0.9% Sodium-chloride; Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min; Glucagon 12.5ng/kg/min", "enrollment": "10", "startDate": "2022-01-18", "completionDate": "2022-10-07", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT04307797" }, { "nctId": "NCT05110794", "title": "A Multiple-Dose Study of LY3502970 in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "LY3502970", "enrollment": "34", "startDate": "2021-11-05", "completionDate": "2022-02-10", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05110794" }, { "nctId": "NCT05051566", "title": "A Multiple Dose Study of LY3502970 in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "LY3502970; Esomeprazole", "enrollment": "26", "startDate": "2021-09-16", "completionDate": "2022-04-04", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT05051566" }, { "nctId": "NCT04897802", "title": "Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)", "status": "Completed", "phase": "PHASE4", "sponsor": "Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau", "conditions": "Hypopituitarism; Central Diabetes Insipidus; Panhypopituitarism; Psychological Disorder; Social Isolation; Hypothalamic Diseases; Pituitary Diseases; Oxytocin Deficiency", "interventions": "Experimental: GLP1-RA (exenatide) administration; Control: Placebo administration", "enrollment": "42", "startDate": "2021-09-13", "completionDate": "2024-04-30", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT04897802" }, { "nctId": "NCT04982575", "title": "Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes", "status": "Completed", "phase": "PHASE2", "sponsor": "Novo Nordisk A/S", "conditions": "Diabetes Mellitus, Type 2", "interventions": "Semaglutide 2.4 mg; Cagrilintide 2.4 mg; Placebo (semaglutide); Placebo (cagrilintide)", "enrollment": "92", "startDate": "2021-08-02", "completionDate": "2022-07-07", "hasResults": "yes", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT04982575" }, { "nctId": "NCT05220917", "title": "Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study", "status": "Active not recruiting", "phase": "N/A", "sponsor": "Brigham and Women's Hospital", "conditions": "Cardiovascular Events; Type2 Diabetes; Renal Disease", "interventions": "SGLT2 inhibitor; DPP-4 inhibitor; GLP-1RA; 2nd generation SU", "enrollment": "781430", "startDate": "2021-08-01", "completionDate": "2026-05-31", "hasResults": "no", "compounds": "liraglutide; dulaglutide; exenatide", "url": "https://clinicaltrials.gov/study/NCT05220917" }, { "nctId": "NCT04731272", "title": "GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance", "status": "Recruiting", "phase": "PHASE2", "sponsor": "University of Pennsylvania", "conditions": "Cystic Fibrosis; Pancreatic Insufficiency; Abnormal Glucose Tolerance; Diabetes", "interventions": "Dulaglutide 0.75Mg/0.5Ml Inj Pen", "enrollment": "30", "startDate": "2021-07-16", "completionDate": "2027-06-30", "hasResults": "no", "compounds": "dulaglutide", "url": "https://clinicaltrials.gov/study/NCT04731272" }, { "nctId": "NCT04940078", "title": "A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity", "status": "Completed", "phase": "PHASE1", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity & Overweight", "interventions": "Cagrilintide; semaglutide; Cagrilintide and semaglutide", "enrollment": "40", "startDate": "2021-07-07", "completionDate": "2022-01-19", "hasResults": "no", "compounds": "cagrilintide", "url": "https://clinicaltrials.gov/study/NCT04940078" }, { "nctId": "NCT05073692", "title": "Comparison of Type 2 Diabetes Pharmacotherapy Regimens", "status": "Completed", "phase": "N/A", "sponsor": "Kaiser Permanente", "conditions": "Type 2 Diabetes Mellitus; Cardiovascular Diseases", "interventions": "SU; DPP4; SGLT2i; GLP-1RA; SGLT2i or GLP-1RA; Linagliptin (DPP4); Exenatide (GLP-1RA); Liraglutide (GLP-1RA); Empagliflozin (SGLT2i); Glimepiride (SU); Glipizide (SU); Glimepiride (SU) or Glipizide (SU); SU or DPP4 (excluding saxagliptin and alogliptin); Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)", "enrollment": "241981", "startDate": "2021-07-01", "completionDate": "2024-12-31", "hasResults": "yes", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT05073692" }, { "nctId": "NCT04952779", "title": "Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea", "status": "Completed", "phase": "N/A", "sponsor": "Novo Nordisk A/S", "conditions": "Diabetes Mellitus, Type 2", "interventions": "Xultophy® (insulin degludec/liraglutide)", "enrollment": "750", "startDate": "2021-06-02", "completionDate": "2024-12-15", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT04952779" }, { "nctId": "NCT04823208", "title": "A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Diabetes Mellitus, Type 2", "interventions": "LY3437943; Placebo", "enrollment": "64", "startDate": "2021-05-24", "completionDate": "2022-06-23", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT04823208" }, { "nctId": "NCT04881760", "title": "A Study of LY3437943 in Participants Who Have Obesity or Are Overweight", "status": "Completed", "phase": "PHASE2", "sponsor": "Eli Lilly and Company", "conditions": "Obesity; Overweight", "interventions": "LY3437943; Placebo", "enrollment": "338", "startDate": "2021-05-20", "completionDate": "2022-05-16", "hasResults": "yes", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT04881760" }, { "nctId": "NCT04777396", "title": "A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)", "status": "Completed", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Early Alzheimer's Disease", "interventions": "Semagludtide; Placebo (semaglutide)", "enrollment": "1840", "startDate": "2021-05-18", "completionDate": "2025-09-16", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT04777396" }, { "nctId": "NCT04867785", "title": "A Study of LY3437943 in Participants With Type 2 Diabetes", "status": "Completed", "phase": "PHASE2", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes", "interventions": "LY3437943; Dulaglutide; Placebo", "enrollment": "281", "startDate": "2021-05-13", "completionDate": "2022-07-08", "hasResults": "yes", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT04867785" }, { "nctId": "NCT04909333", "title": "Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia", "status": "Completed", "phase": "NA", "sponsor": "University Hospital, Basel, Switzerland", "conditions": "Endogenous Hyperinsulinism", "interventions": "Exenatide; 0.9% saline solution", "enrollment": "29", "startDate": "2021-04-29", "completionDate": "2024-04-30", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT04909333" }, { "nctId": "NCT04822181", "title": "Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Non-alcoholic Steatohepatitis", "interventions": "Semaglutide; Placebo", "enrollment": "1205", "startDate": "2021-04-01", "completionDate": "2029-04-25", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT04822181" }, { "nctId": "NCT04639414", "title": "Combined Active Treatment in Type 2 Diabetes With NASH", "status": "Completed", "phase": "PHASE4", "sponsor": "German Diabetes Center", "conditions": "Type 2 Diabetes; Non-alcoholic Steatohepatitis (NASH); Non-alcoholic Fatty Liver Disease (NAFLD)", "interventions": "Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector; Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide; Placebo matching empagliflozin and placebo pen injector matching semaglutide", "enrollment": "192", "startDate": "2021-03-26", "completionDate": "2025-01-31", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT04639414" }, { "nctId": "NCT04775082", "title": "SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "Liraglutide; Placebo", "enrollment": "78", "startDate": "2021-03-04", "completionDate": "2023-08-01", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT04775082" }, { "nctId": "NCT04520490", "title": "Brain Activation and Satiety in Children 2", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "Seattle Children's Hospital", "conditions": "Childhood Obesity", "interventions": "Family Based Behavioral Treatment; Exenatide 2 mg [Bydureon]; Placebo", "enrollment": "63", "startDate": "2021-01-28", "completionDate": "2025-08-21", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT04520490" }, { "nctId": "NCT04575844", "title": "Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome", "status": "Recruiting", "phase": "PHASE4", "sponsor": "University of Virginia", "conditions": "Metabolic Syndrome", "interventions": "Liraglutide; Exercise training; Liraglutide + Exercise training", "enrollment": "80", "startDate": "2020-11-01", "completionDate": "2027-04-30", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT04575844" }, { "nctId": "NCT04426474", "title": "A Study of LY3502970 in Participants With Type 2 Diabetes", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Diabetes Mellitus, Type 2", "interventions": "LY3502970; Placebo", "enrollment": "68", "startDate": "2020-10-08", "completionDate": "2021-07-12", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT04426474" }, { "nctId": "NCT04431713", "title": "Exenatide Once-weekly as a Treatment for Multiple System Atrophy", "status": "Completed", "phase": "PHASE2", "sponsor": "University College, London", "conditions": "Multiple System Atrophy", "interventions": "Exenatide Pen Injector [Bydureon]", "enrollment": "50", "startDate": "2020-09-16", "completionDate": "2024-03-22", "hasResults": "yes", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT04431713" }, { "nctId": "NCT04255433", "title": "A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes", "status": "Completed", "phase": "PHASE3", "sponsor": "Eli Lilly and Company", "conditions": "Type 2 Diabetes Mellitus", "interventions": "Tirzepatide; Dulaglutide", "enrollment": "13299", "startDate": "2020-05-29", "completionDate": "2025-06-12", "hasResults": "yes", "compounds": "tirzepatide; dulaglutide", "url": "https://clinicaltrials.gov/study/NCT04255433" }, { "nctId": "NCT04154072", "title": "A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease", "status": "Completed", "phase": "PHASE2", "sponsor": "Neuraly, Inc.", "conditions": "Parkinson Disease", "interventions": "NLY01; Vehicle", "enrollment": "255", "startDate": "2020-02-27", "completionDate": "2023-02-14", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT04154072" }, { "nctId": "NCT04232969", "title": "Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease", "status": "Completed", "phase": "PHASE3", "sponsor": "University College, London", "conditions": "Parkinson's Disease", "interventions": "Exenatide extended release 2mg (Bydureon)", "enrollment": "194", "startDate": "2020-01-20", "completionDate": "2024-02-24", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT04232969" }, { "nctId": "NCT04143802", "title": "A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Diabetes Mellitus, Type 2", "interventions": "LY3437943; Dulaglutide; Placebo", "enrollment": "72", "startDate": "2019-12-18", "completionDate": "2020-12-28", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT04143802" }, { "nctId": "NCT03884075", "title": "Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)", "status": "Recruiting", "phase": "PHASE2", "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "conditions": "Non-Alcoholic Steatohepatitis; Non-Alcoholic Fatty Liver Disease", "interventions": "Semaglutide", "enrollment": "104", "startDate": "2019-07-24", "completionDate": "2026-08-31", "hasResults": "no", "compounds": "semaglutide", "url": "https://clinicaltrials.gov/study/NCT03884075" }, { "nctId": "NCT03929744", "title": "A Study of LY3502970 in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "LY3502970; Placebo; Atorvastatin; Simvastatin; Midazolam", "enrollment": "133", "startDate": "2019-06-12", "completionDate": "2020-11-02", "hasResults": "yes", "compounds": "orforglipron", "url": "https://clinicaltrials.gov/study/NCT03929744" }, { "nctId": "NCT03923114", "title": "Imaging Pituitary ActiVation by Exendin", "status": "Completed", "phase": "NA", "sponsor": "Radboud University Medical Center", "conditions": "Diabetes Mellitus, Type 2", "interventions": "Ga-68-NODAGA-exendin-4 PET/CT", "enrollment": "20", "startDate": "2019-05-23", "completionDate": "2024-04-03", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT03923114" }, { "nctId": "NCT03856632", "title": "Liraglutide Effect in Atrial Fibrillation", "status": "Active not recruiting", "phase": "PHASE4", "sponsor": "University of Miami", "conditions": "Atrial Fibrillation", "interventions": "Liraglutide; RFM; Anti Arrhythmics; Afib Catheter Ablation", "enrollment": "60", "startDate": "2019-03-18", "completionDate": "2026-12-31", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT03856632" }, { "nctId": "NCT03841630", "title": "A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants", "status": "Completed", "phase": "PHASE1", "sponsor": "Eli Lilly and Company", "conditions": "Healthy", "interventions": "LY3437943; Placebo", "enrollment": "45", "startDate": "2019-03-13", "completionDate": "2019-07-25", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT03841630" }, { "nctId": "NCT06725693", "title": "Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease", "status": "Recruiting", "phase": "N/A", "sponsor": "Tianjin Medical University", "conditions": "GLP1-R-related Disease; Tumor; Insulinoma; Positron Emission Tomography", "interventions": "18F/68Ga-Exendin 4", "enrollment": "500", "startDate": "2019-02-01", "completionDate": "2027-11-01", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT06725693" }, { "nctId": "NCT03498001", "title": "Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging", "status": "Completed", "phase": "NA", "sponsor": "Centre Hospitalier Universitaire Dijon", "conditions": "Type II Diabetes", "interventions": "GLP-1 agonists; Cardiac MRI; Follow up by phone", "enrollment": "42", "startDate": "2018-04-16", "completionDate": "2023-06-06", "hasResults": "no", "compounds": "liraglutide; dulaglutide", "url": "https://clinicaltrials.gov/study/NCT03498001" }, { "nctId": "NCT03492580", "title": "A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease", "status": "Completed", "phase": "N/A", "sponsor": "Janssen Research & Development, LLC", "conditions": "Diabetes Mellitus, Type 2; Cardiovascular Diseases", "interventions": "Canagliflozin; Empagliflozin; Dapagliflozin; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Glucagon-like Peptide-1 (GLP-1) Agonist; Anti-hyperglycemic Agents (AHA); Thiazolidinediones (TZD); Sulfonylureas (SU); Insulin", "enrollment": "714582", "startDate": "2018-02-22", "completionDate": "2018-04-06", "hasResults": "no", "compounds": "dulaglutide; exenatide", "url": "https://clinicaltrials.gov/study/NCT03492580" }, { "nctId": "NCT03878706", "title": "The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination", "status": "Recruiting", "phase": "N/A", "sponsor": "University of Athens", "conditions": "Diabetes Mellitus, Type 2", "interventions": "", "enrollment": "240", "startDate": "2017-11-03", "completionDate": "2026-12-31", "hasResults": "no", "compounds": "liraglutide; mots-c", "url": "https://clinicaltrials.gov/study/NCT03878706" }, { "nctId": "NCT02860923", "title": "Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy", "status": "Completed", "phase": "PHASE3", "sponsor": "University Hospital, Bordeaux", "conditions": "Craniopharyngiomas; Hypothalamic Obesity", "interventions": "Exenatide; Placebo", "enrollment": "42", "startDate": "2017-01-11", "completionDate": "2018-06-30", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT02860923" }, { "nctId": "NCT02944500", "title": "Saxenda: Underlying Mechanisms and Clinical Outcomes", "status": "Active not recruiting", "phase": "PHASE4", "sponsor": "Beth Israel Deaconess Medical Center", "conditions": "Obesity", "interventions": "liraglutide; Placebo", "enrollment": "28", "startDate": "2016-11", "completionDate": "2027-06", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT02944500" }, { "nctId": "NCT05762744", "title": "Pharmacogenomics of GLP1 Receptor Agonists", "status": "Terminated", "phase": "PHASE1", "sponsor": "University of Maryland, Baltimore", "conditions": "Type 2 Diabetes", "interventions": "Exenatide Injection (before the first FSIGT); Exenatide injection before the second FSIGT)", "enrollment": "63", "startDate": "2016-06-01", "completionDate": "2018-11-30", "hasResults": "yes", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT05762744" }, { "nctId": "NCT02773355", "title": "Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients", "status": "Completed", "phase": "N/A", "sponsor": "Novo Nordisk A/S", "conditions": "Obesity", "interventions": "liraglutide 3.0 mg", "enrollment": "27", "startDate": "2016-05-16", "completionDate": "2021-11-30", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT02773355" }, { "nctId": "NCT02673931", "title": "GLP-1 and Hyperoxia for Organ Protection in Heart Surgery", "status": "Active not recruiting", "phase": "NA", "sponsor": "Rigshospitalet, Denmark", "conditions": "Coronary Disease; Shock, Cardiogenic; Renal Failure; Stroke; Brain Injury; Aortic Valve Disease", "interventions": "Byetta (Lilly, Exenatide); Conoxia (AGA, oxygen); 20% Human Albumin", "enrollment": "1400", "startDate": "2016-02", "completionDate": "2024-09", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT02673931" }, { "nctId": "NCT02251431", "title": "Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome", "status": "Completed", "phase": "PHASE3", "sponsor": "Baylor Research Institute", "conditions": "Type 2 Diabetes Mellitus; Chronic Kidney Disease; Left Ventricular Diastolic Dysfunction", "interventions": "BYDUREON; Placebo", "enrollment": "57", "startDate": "2015-11", "completionDate": "2019-12", "hasResults": "yes", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT02251431" }, { "nctId": "NCT02157974", "title": "Liver and Fat Regulation in Overweight Adolescent Girls", "status": "Completed", "phase": "PHASE2/PHASE3", "sponsor": "University of Colorado, Denver", "conditions": "Hepatic Steatosis; Polycystic Ovarian Syndrome; Obesity", "interventions": "Byetta 5Mcg Pen Injection", "enrollment": "92", "startDate": "2014-08", "completionDate": "2022-12", "hasResults": "yes", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT02157974" }, { "nctId": "NCT02674893", "title": "Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes", "status": "Terminated", "phase": "PHASE4", "sponsor": "Centre Hospitalier Universitaire Dijon", "conditions": "Type 2 Diabetes; Overweight", "interventions": "Liraglutide; Observation alone", "enrollment": "48", "startDate": "2014-02-04", "completionDate": "2016-08-31", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT02674893" }, { "nctId": "NCT01794143", "title": "A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes", "status": "Completed", "phase": "PHASE3", "sponsor": "GRADE Study Group", "conditions": "Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications", "interventions": "Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin); GLP-1 receptor agonist (liraglutide); Insulin (glargine)", "enrollment": "7850", "startDate": "2013-05", "completionDate": "2021-04-30", "hasResults": "yes", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT01794143" }, { "nctId": "NCT02721888", "title": "Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism", "status": "Terminated", "phase": "PHASE4", "sponsor": "Centre Hospitalier Universitaire Dijon", "conditions": "Type 2 Diabetes", "interventions": "Liraglutide; MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy); Blood sample; Kinetic substudy (10 patients)", "enrollment": "127", "startDate": "2012-07-10", "completionDate": "2019-10-02", "hasResults": "no", "compounds": "liraglutide", "url": "https://clinicaltrials.gov/study/NCT02721888" }, { "nctId": "NCT02042664", "title": "Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics", "status": "Completed", "phase": "PHASE3", "sponsor": "Assistance Publique Hopitaux De Marseille", "conditions": "Obesity; Diabetes", "interventions": "BYETTA treatment; Metformine", "enrollment": "44", "startDate": "2011-01", "completionDate": "2015-01", "hasResults": "no", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT02042664" }, { "nctId": "NCT01107717", "title": "Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM", "status": "Completed", "phase": "PHASE4", "sponsor": "The University of Texas Health Science Center at San Antonio", "conditions": "Diabetes", "interventions": "metformin\\pioglitazone\\exenatide; metformin, glyburide and glargine", "enrollment": "318", "startDate": "2009-01", "completionDate": "2023-02-03", "hasResults": "yes", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT01107717" }, { "nctId": "NCT00679042", "title": "Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol", "status": "Active not recruiting", "phase": "PHASE3", "sponsor": "CellTrans Inc.", "conditions": "Type 1 Diabetes Mellitus", "interventions": "Islets of Langerhans transplantation", "enrollment": "21", "startDate": "2007-09-05", "completionDate": "2017-07-19", "hasResults": "yes", "compounds": "exenatide", "url": "https://clinicaltrials.gov/study/NCT00679042" }, { "nctId": "NCT07677865", "title": "GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation", "status": "Completed", "phase": "N/A", "sponsor": "West China Hospital", "conditions": "Alzheimer Disease; Diabetes Mellitus Type 2; Obesity & Overweight", "interventions": "GLP-1 Receptor Agonists; DPP-4 Inhibitors", "enrollment": "213891", "startDate": "2007-01-01", "completionDate": "2024-12-31", "hasResults": "no", "compounds": "semaglutide; tirzepatide; liraglutide", "url": "https://clinicaltrials.gov/study/NCT07677865" }, { "nctId": "NCT07629401", "title": "Provide Pre-approval Expanded Access of LY3437943", "status": "Available", "phase": "N/A", "sponsor": "Eli Lilly and Company", "conditions": "", "interventions": "Retatrutide", "enrollment": "", "startDate": "", "completionDate": "", "hasResults": "no", "compounds": "retatrutide", "url": "https://clinicaltrials.gov/study/NCT07629401" } ] }